PORT WASHINGTON, N.Y. – March 13, 2019: Pall Corporation, a global leader in filtration, separation and purification, announced the next step in the collaboration agreement with ARTeSYN Biosolutions, a leading innovator in single-use components and fluid management technologies. Under this co-exclusive agreement, the Pall Biotech line of business will immediately distribute ARTeSYN’s standard hardware and liner components off the shelf. ARTeSYN valves offer unmatched biopharmaceutical fluid flow control, with a compact, durable single-use design for simple installation and maintenance.


This co-distribution agreement with ARTeSYN Biosolutions is a critical element of our partnering program, and complements Pall’s existing Allegro™ integrated single-use portfolio of upstream, downstream and final filling solutions,” said Ed Hoare, Senior Vice President, Pall Biotech. “Customers will benefit from the flexibility, agility and reliability required for their bioprocessing journey. The agreement also helps to accelerate the implementation of robust and standardized single-use fluid management and controls, which has been an industry challenge for decades.”


“Adoption of single-use technology continues to grow within the cGMP clinical and commercial manufacturing space. This collaboration reflects our focus on accelerating single-use technology adoption for more efficient production of life saving drugs,” Michael Gagne, ARTeSYN Biosolutions founder and CXO commented. “We are excited to work with Pall, a company with which we share similar goals to offer innovative biotech solutions and an outstanding global commercial, technical and validation support network.”


The valves and fluid handling technologies are currently available to complement the Allegro™ single-use solutions portfolio. Learn more, or place an order.



About Pall Corporation

Pall Corporation is a filtration, separation and purification leader, providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com, or on YouTube, LinkedIn, Twitter, or Facebook.


About Artesyn Biosolutions

Artesyn Biosolutions, a privately held company, is a visionary brand in the area of single-use solutions for bioprocessing. ARTeSYN® has created a series of solutions targeting the voids and expanding the possibilities in the existing single-use space with the goal of enabling abundance in medicine. These solutions include patented and patent-pending valves, instruments, XO® skeletal supports, along with conventional unit operation systems like tangential flow filtration, chromatography, media and buffer prep in single-use formats that use these newly minted component solutions in their most advanced forms.


For more information, please visit www.artesynbiosolutions.com or follow us on Facebook, LinkedIn, Google+ or Twitter.


Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Media Contact

White Matter Communications

Beth Willers




ARTeSYN Biosolutions Contact

Liis Oblikas



더 Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.